 MONMOUTH JUNCTION, N.J., Nov. 05, 2020 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the issuance of a 10.2 million unsecured promissory note the Note to an accredited investor for 10.0 million cash proceeds, which will be used to pay off existing demand notes and to provide additional working capital. 